Our impact on dementia research
Getting access to the best quality data is one of the biggest difficulties facing dementia researchers today. In our first five years, we've worked to break down these barriers by opening up access to detailed datasets.
The power of research studies in dementia
The new era of using complex datasets for dementia research is here. These exemplars, from the 55 approved studies in the Data Portal, use the statistical power in multiple health studies to address the urgent questions in dementia research.
Read moreTests to bring out the best of existing health studies
Thanks to partnerships with two industry companies offering cognitive test technology, DPUK cohorts can now access online or iPad-based software to collect information on their participants' thinking and memory skills. The opportunity allows cohorts to enhance their data and optimise for use in research.
Read more'This superagers dataset will be available to other researchers.'
Dr Sarah Bauermeister is part of an international team of collaborators who are combining data from several cohorts in the Data Portal.
Read more'We're creating a database of new measures which we'll share with the original cohort.'
Amanda Worker works on a DPUK-funded project looking into the links between heart and brain health. The team have analysed thousands of scans as part of their work.
Read more'We have access to data spanning tens of years.'
Dr Ivan Koychev leads the development of DPUK's Great Minds register. Great Minds uses the power of DPUK cohorts to pave the way for highly-specific drug trials for dementia.
Read more
Our work advances data access and fast-tracks science
Latest publications
DPUK tools and resources are the foundation for a wide range of research studies in dementia.
DPUK resources experimental medicine for dementia
Enabling participation in research
The foundation of multicentre research
Funded and enabled studies
New spaces for new ideas
By providing the opportunity for academic and industry scientists to get to together, DPUK's research communities have broken down traditional barriers and nurtured innovative collaborations.
Repurposing the drug libraries
Using the patient-specific cell models derived from DPUK cohorts, a joint research team is investigating the behaviour of drugs developed by AstraZeneca (AZ) to identify new avenues for treatments.
Joining up the dots
DPUK investment has enabled scientists to study the development of brain disease using a type of stem cell derived from the blood samples of cohort study participants.